Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  1999-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2036.1999.00666.xPMID 10594402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii.

  2000cited by this paper
• Pharmacokinetics of Biotherapeutic Agents

  1999cited by this paper
• Biotherapeutic Agents and Infectious Diseases

  1999cited by this paper
• Recurrent Clostridium Difficile Disease: Epidemiology and Clinical Characteristics

  1999cited by this paper
• Health benefits of probiotics

  1998cited by this paper
• Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease

  1998cited by this paper
• Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children.

  1997cited by this paper
• Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections.

  1996cited by this paper
• Saccharomyces boulardii is not Saccharomyces cerevisiae.

  1996cited by this paper
• Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo.

  1995cited by this paper
• FDA Recalls Blood Products After Donor Diagnosed with Creutzfeldt-Jakob Disease

  1995cited by this paper
• Elimination of Gowning in Neonatal Intensive Care Does Not Affect Infection Rates or Hand- Washing Patterns-Saves $120,000 Annually

  1995cited by this paper
• Lactobacillus GG vaginal suppositories and vaginitis.

  1995cited by this paper
• Effect of Supplements with Bifidobacterium longum and Lactobacillus acidophilus on the Intestinal Microbiota during Administration of Clindamycin

  1994cited by this paper
• A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

  1994cited by this paper
• Recovery and Elimination of the Biotherapeutic Agent, Saccharomyces boulardii, in Healthy Human Volunteers

  1993cited by this paper
• [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study].

  1993cited by this paper
• Influence of three-day antimicrobial therapy and lactobacillus vaginal suppositories on recurrence of urinary tract infections.

  1992cited by this paper
• Ingestion of Yogurt Containing Lactobacillus acidophilus as Prophylaxis for Candidal Vaginitis

  1992cited by this paper
• Survival of Lactobacillus species (strain GG) in human gastrointestinal tract.

  1992cited by this paper
• [Survival of Lactobacillus acidophilus and Bifidobacterium sp. in the small intestine following ingestion in fermented milk. A rational basis for the use of probiotics in man].

  1992cited by this paper
• Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice.

  1991cited by this paper
• A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children.

  1991cited by this paper
• Influence of Antibiotics on the Recovery and Kinetics of Saccharomyces boulardii in Rats

  1991cited by this paper
• Prevention of travellers' diarrhoea by Lactobacillus GG.

  1990cited by this paper
• Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea.

  1990cited by this paper
• Disposition kinetics of Saccharomyces boulardii in man and rat.

  1989cited by this paper
• Impact of Lactobacillus acidophilus supplements on the human oropharyngeal and intestinal microflora.

  1987cited by this paper

• Evaluation of the delivery of an anti-Listeria endolysin via CRISPR-Cas9 engineered probiotic Saccharomyces boulardii

  2026cites this paper
• Genetic engineering of Saccharomyces boulardii: Tools, strategies and advances for enhanced probiotic and therapeutic applications.

  2025cites this paper
• Engineered Probiotic Saccharomyces boulardii Reduces Colitis-Associated Colorectal Cancer Burden in Mice

  2025cites this paper
• Antibiotic-associated dysbiosis: modern strategy for microbiota restoration. A review

  2024cites this paper
• Yeast oral vaccines against infectious diseases

  2023cites this paper
• The impact of a fermented diet including Iraqi probiotics on a few productive characteristics in Chinese ducks

  2023cites this paper
• Probiotics: health safety considerations

  2022cites this paper
• How Gut Bacterial Dysbiosis Can Promote Candida albicans Overgrowth during Colonic Inflammation

  2022cites this paper
• Health-promoting properties of Saccharomyces cerevisiae var. boulardii as a probiotic; characteristics, isolation, and applications in dairy products

  2021cites this paper
• Probiotic yeast BR14 ameliorates DSS-induced colitis by restoring the gut barrier and adjusting the intestinal microbiota.

  2021cites this paper
• Production of neoagarooligosaccharides by probiotic yeast Saccharomyces cerevisiae var. boulardii engineered as a microbial cell factory

  2021cites this paper
• Impact of Probiotics on microbiota in the gut of antibiotic treated Vertebrates

  2021cites this paper
• Recovery of Saccharomyces cerevisiae CNCM I-3856 in Vaginal Samples of Healthy Women after Oral Administration

  2020cites this paper
• A probiotic yeast-based immunotherapy against Clostridioides difficile infection

  2020cites this paper
• An introduction of the role of probiotics in human infections and autoimmune diseases

  2019influential citation
• Saccharomyces boulardii inhibits the expression of pro-inflammatory cytokines and inducible nitric oxide synthase genes in the colonic mucosa of rats experimentally-infected with Blastocystis subtype-3 cysts

  2019cites this paper
• Clostridium difficile Colitis Prevention and Treatment.

  2019cites this paper
• Effect of Carbon Sources, Nitrogen Sources and Prebiotics on Growth of Saccharomyces Boulardii

  2019cites this paper
• Different host factors are associated with patterns in bacterial and fungal gut microbiota in Slovenian healthy cohort

  2018cites this paper
• Application of Saccharomyces cerevisiae var. boulardii in food processing: a review

  2018cites this paper
• Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.

  2017cites this paper
• Common Organisms and Probiotics: Saccharomyces boulardii

  2017cites this paper
• Lactic Acid Bacteria and Fermentation of Cereals and Pseudocereals

  2017cites this paper
• Survie et pathogénicité des EHEC dans l'environnement digestif : Interactions avec le microbiote et l'épithélium intestinal. : Influence de l'administration de levures probiotiques.

  2015cites this paper
• Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis – a review

  2015cites this paper
• Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota

  2015cites this paper
• Modulation of intestinal microbiota in mice by kefir administration

  2015cites this paper
• Saccharomyces boulardii ’ nin Fermente Süt Ürünlerinde Kullanımı

  2014cites this paper
• Bacterial counts from five over-the-counter probiotics: are you getting what you paid for?

  2014cites this paper
• Treatment of recurrent Clostridium difficile infection: a systematic review

  2014cites this paper
• Effect of whey protein agglomeration on spray dried microcapsules containing Saccharomyces boulardii.

  2013cites this paper
• Molecular understanding of whey protein-based matrices for the preservation of saccharomyces boulardii cells in spray dried microcapsules

  2013cites this paper
• Investigating the role of intestinal microflora in the aetiology, symptom scores and life quality of people with coeliac disease

  2013cites this paper
• Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.

  2013cites this paper
• Yeasts from kefir grains: isolation, identification, and probiotic characterization

  2013cites this paper
• Antimicrobial and Probiotic Properties of Yeasts: From Fundamental to Novel Applications

  2012cites this paper
• Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders

  2012cites this paper
• Use of Artificial Digestive Systems to Investigate the Biopharmaceutical Factors Influencing the Survival of Probiotic Yeast During Gastrointestinal Transit in Humans

  2012cites this paper
• Is primary prevention of Clostridium difficile infection possible with specific probiotics?

  2012cites this paper
• Saccharomyces boulardii viability and efficacy in horses with antimicrobial-induced diarrhoea

  2012cites this paper
• The Nutritional Status of Patients with Clostridium Difficile Associeated Disease and Dietetic Practices Concerning the Management of These Patients

  2012cites this paper
• PROBİYOTİK MAYA : SACCHAROMYCES BOULARDİİ

  2012cites this paper
• Probiotics in clostridium difficile Infection.

  2011cites this paper
• Probiotics and prebiotics in prevention and treatment of diseases in infants and children.

  2011cites this paper
• Probiotics in Clostridium difficile Infection

  2011cites this paper
• Safety of Probiotics to Reduce Risk and Prevent or Treat Disease

  2011cites this paper
• Saccharomyces boulardii REVERTE A RESPOSTA INFLAMATÓRIA E FUNCIONAL PRESENTE NA MUCOSITE INTESTINAL INDUZIDA POR 5-FLUOROURACIL EM CAMUNDONGOS

  2011cites this paper
• Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

  2010cites this paper
• Quality control of fifteen probiotic products containing Saccharomyces boulardii

  2010cites this paper
• Saccharomyces boulardii module les propriétés des cellules dendritiques et le déséquilibre du microbiote intestinal après un traitement antibiotique

  2010cites this paper
• [Saccharomyces boulardii modulates dendritic cell properties and intestinal microbiota disruption after antibiotic treatment].

  2010cites this paper
• Coated whey protein/alginate microparticles as oral controlled delivery systems for probiotic yeast

  2010cites this paper
• Über den therapeutischen Nutzen von Hefezellen-ein historischer Überblick

  2010cites this paper
• Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections.

  2009cites this paper
• THE USE OF LACTOBACILLUS IN THE TREATMENT OF CLOSTRIDIUM DIFFICILE INFECTION IN HOSPITALIZED ADULT PATIENTS

  2009cites this paper
• O probiótico Saccharomyces boulardii

  2009cites this paper
• Probiotics, immune function, infection and inflammation: a review of the evidence from studies conducted in humans.

  2009cites this paper
• Physiological characterization of non-Saccharomyces yeasts from agro-industrial and environmental origins with possible probiotic function

  2009cites this paper
• Saccharomyces boulardii in a child with recurrent Clostridium difficile

  2009cites this paper
• Saccharomyces boulardii in childhood

  2009cites this paper
• Probiotics for treatment of Clostridium difficile-associated colitis in adults.

  2008cites this paper
• Influence of pH conditions on the viability of Saccharomyces boulardii yeast.

  2008cites this paper
• Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii.

  2008cites this paper
• Increased Intestinal Delivery of Viable Saccharomyces boulardii by Encapsulation in Microspheres

  2008cites this paper
• Current and future treatment modalities for Clostridium difficile-associated disease.

  2008cites this paper
• Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition.

  2008cites this paper
• article : yeast as probiotics – Saccharomyces boulardii

  2007cites this paper
• Review article: yeast as probiotics –Saccharomyces boulardii

  2007cites this paper
• Saccharomyces cerevisiae strain 905 reduces the translocation of Salmonella enterica serotype Typhimurium and stimulates the immune system in gnotobiotic and conventional mice.

  2007cites this paper
• Control bioecológico y nutricional de la enfermedad: prebióticos, probióticos y simbióticos

  2006cites this paper
• Bioecological and nutritional control of disease: prebiotics, probiotics and synbiotics.

  2006cites this paper
• Probiotics as biopreservatives for enhancing food safety.

  2006cites this paper
• Probiotics Used in Human Studies

  2005cites this paper
• Probiotics: wanted dead or alive.

  2005cites this paper
• Utilização de leveduras como probióticos

  2005cites this paper
• Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice.

  2005cites this paper
• THE USE OF PROBIOTICS IN THE PREVENTION AND TREATMENT OF CLOSTRIDIUM DIFFICILE DIARRHEA

  2005cites this paper
• Estudo do potencial probiótico de linhagens de saccharomyces cerevisiae através de testes in vitro

  2005cites this paper
• Bioecologic control of the gastrointestinal tract: the role of flora and supplemented probiotics and synbiotics.

  2005cites this paper
• Probiotics and Prebiotics

  2004cites this paper
• The taxonomic position of Saccharomyces boulardii as evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-ITS2 region and the mitochondrial cytochrome-c oxidase II gene.

  2003cites this paper
• Probiotics and Clostridium difficile-associated diarrhoea

  2003cites this paper
• Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study

  2002cites this paper
• Biotherapeutic agents in the treatment of infectious diarrhea.

  2001cites this paper
• Preclinical and Clinical Pharmacology of Biotherapeutic Agents: Saccharomyces boulardii

  2001cites this paper
• Treatment options in Clostridium difficile infection

  2001cites this paper
• Food processing: probiotic microorganisms for beneficial foods.

  2001cites this paper
• Non-antibiotic therapy for Clostridium difficile infection.

  2000cites this paper
• Update on gastrointestinal infections: clostridium difficile and other bugs

  1999cites this paper
• Clinical and Experimental Gastroenterology Dovepress

  year unknowncites this paper
• Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections q

  year unknowncites this paper